Objectives. We sought to assess the odds of experiencing adverse effects with low dose
amiodarone therapy compared with placebo. Background. An estimate of the likelihood of …

Antiarrhythmic strategies have changed dramatically during the last decade. The Cardiac
Arrhythmia Suppres-Ž. sion Trial CAST reported the harmful effects of flecainide, encainide …

The clinical outcome of 52 consecutive patients with hypertrophic cardiomyopathy who
developed paroxysmal (< 1 week) or established (≥ l week) atrial fibrillation between 1960 …

In view of the high risk of sudden cardiac death and the prognostic importance of complex
ventricular ectopic activity, the effects of prophylactic antiarrhythmic treatment were …

Interest in amiodarone has increased because of its remarkable efficacy as an
antiarrhythmic agent. The purpose of this report is to review what is known about the …

Purpose: To review the pharmacology, electrophysiology, and toxicity of amiodarone and to
discuss the clinical results produced when amiodarone is used as therapy for patients with …

The relationship of apparent steady-state serum concentrations of amiodarone and its
metabolite, desethylamiodarone, to therapeutic and toxic effects was assessed in 127 …

Atrial fibrilation (AF) is a difficult arrhythmia to manage with antiarrhythmic agents.
Amiodarone is highly effective in restoring and maintaining normal sinus rhythm in patients …

Amiodarone is a unique antiarrhythmic agent originally developed as a vasodilator.
Classified electrophysiologically as a Type III antiarrhythmic, it also has both nonspecific …

The computed tomographic (CT) chest scans of 11 patients who developed respiratory or
constitutional symptoms while receiving amiodarone therapy were reviewed. CT findings …